Codexis and India's Matrix Laboratories sign second agreement
Codexis, a privately-held biotechnology company headquartered in the US, has signed a second agreement expanding its collaboration with India's Matrix Laboratories, a major provider of active pharmaceutical ingredients (APIs).
Codexis, a privately-held biotechnology company headquartered in the US, has signed a second agreement expanding its collaboration with India's Matrix Laboratories, a major provider of active pharmaceutical ingredients (APIs).
The deal covers a collaboration on the development and commercialisation of a novel process for a second major undisclosed pharmaceutical product. The two companies announced a similar agreement for a separate API back in June 2005.
Codexis will employ its proprietary pharmaceutical process re-engineering technology platform to develop a novel synthetic process for the product using one of its Thoroughbred-trademarked biocatalysts. The process will be transferred to Matrix for final scale-up and manufacturing, and Matrix will receive exclusive manufacturing and marketing rights to the novel process being developed.